FDA to Expand Least Burdensome Approach Across Product Lifecycle

The GMP Letter
A A
The FDA said in a new draft guidance a “least burdensome” approach should be applied throughout the medical device total product lifecycle, rather than just in premarket activities.

To View This Article:

Login

Subscribe To The GMP Letter